Skip to main content
MyPART - My Pediatric and Adult Rare Tumor Network

Featured Clinical Trials

This page highlights some of the clinical trials that are currently enrolling participants with rare tumors. Clinical trials are research studies that involve human volunteers. The data we gain from clinical trials are important for learning more about rare tumors and finding new treatments that work. Learn more about the different types of clinical trials.

NCI-Sponsored Clinical Trials

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

A study that follows patients with rare solid tumors over time to learn about how rare tumors progress and how they affect quality of life. This is a MyPART study. Learn more here.

Testing Atezolizumab in People with Advanced Alveolar Soft Part Sarcoma

A Phase II clinical study testing the ability of the anti-PD-L1 antibody, atezolizumab, in treating patients with ASPS that has spread to other parts of the body and cannot be removed by surgery. This trial is open at many sites across the US for patients ages 14 and older. Patients age 2 and older can enroll at the NIH Clinical Center. We are currently seeking to enroll more pediatric patients at the NIH Clinical Center. Please contact Dr. Mary Frances Wedekind Malone to enroll patients age 2 through 17 by email:

Testing Atezolizumab in Patients >= 2 Years Old With Newly Diagnosed, Unresectable, or Metastatic Clear Cell Sarcoma or Chondrosarcoma

A Phase II trial testing how well atezolizumab works in treating patients 2 years or older with clear cell sarcoma or chondrosarcoma that is newly diagnosed, cannot be removed by surgery, or has spread to other parts of the body. To enroll patients ages 2 through 18, please contact MyPART physician, Dr. Mary Frances Wedekind Malone, at

Now Open to Patients Age 12 and Older: Trial for Relapsed Solid Tumors

A phase 1 study entitled "Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors" is testing the safety of using both drugs, nilotinib and paclitaxel, to treat patients with solid tumors that do not show any response to treatment. In pre-clinical studies, nilotinib was found to show greater anti-tumor activity when used in combination with paclitaxel. This trial is open to people age 12 and older. To be eligible to participate in this study, patients must have completed any radiation or surgery treatments 3 weeks (or longer) prior to starting this study. To enroll patients ages 12-17, please contact MyPART physician, Dr. Mary Frances Wedekind Malone, at

Other Rare Tumor Clinical Trials

TCF-001 TRACK (Target Rare Cancer Knowledge) Study (TRACK)

A study sponsored by MyPART advocacy partner TargetCancer Foundation to determine whether rare cancer patients benefit from DNA sequencing that may help point to a potential precision therapy. 

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Featured Clinical Trials was originally published by the National Cancer Institute.”